A Look At Xenon Pharmaceuticals (XENE) Valuation After Wider Losses And US$400 Million At The Market Offering

Simply Wall St.03-01

Xenon Pharmaceuticals (XENE) is back in focus after reporting wider fourth quarter and full year 2025 losses, followed by a US$400 million at the market follow on equity offering in its common shares....

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2616366821?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-03-01 17:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616366821","market":"hk","top_or_hot":-1,"title":"A Look At Xenon Pharmaceuticals (XENE) Valuation After Wider Losses And US$400 Million At The Market Offering","media":"Simply Wall St.","content":"<div>\n<p>Xenon Pharmaceuticals (XENE) is back in focus after reporting wider fourth quarter and full year 2025 losses, followed by a US$400 million at the market follow on equity offering in its common shares....</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xene/xenon-pharmaceuticals/news/a-look-at-xenon-pharmaceuticals-xene-valuation-after-wider-l\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At Xenon Pharmaceuticals (XENE) Valuation After Wider Losses And US$400 Million At The Market Offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At Xenon Pharmaceuticals (XENE) Valuation After Wider Losses And US$400 Million At The Market Offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-01 17:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xene/xenon-pharmaceuticals/news/a-look-at-xenon-pharmaceuticals-xene-valuation-after-wider-l><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Xenon Pharmaceuticals (XENE) is back in focus after reporting wider fourth quarter and full year 2025 losses, followed by a US$400 million at the market follow on equity offering in its common shares....</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xene/xenon-pharmaceuticals/news/a-look-at-xenon-pharmaceuticals-xene-valuation-after-wider-l\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"XENE","symbol_name":"Xenon制药","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xene/xenon-pharmaceuticals/news/a-look-at-xenon-pharmaceuticals-xene-valuation-after-wider-l","article_id":"2616366821","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xene/xenon-pharmaceuticals/news/a-look-at-xenon-pharmaceuticals-xene-valuation-after-wider-l","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2616366821","pubTimestamp":1772356572,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Xenon Pharmaceuticals (XENE) is back in focus after reporting wider fourth quarter and full year 2025 losses, followed by a US$400 million at the market follow on equity offering in its common shares.\nSee our latest analysis for Xenon Pharmaceuticals.\nThe US$43.23 share price has seen a mixed stretch, with a 5.41% 1 month share price return and a 2.37% 7 day gain, but a modest year to date decline and recent pressure following the wider losses and US$400 million at the market offering...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"XENE":"Xenon制药","BK4139":"生物科技"},"translate_title":"Xenon Pharmaceuticals(XENE)在更大范围亏损和上市发行4亿美元后的估值一览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XENE":1.5},"content_text":"Xenon Pharmaceuticals (XENE) is back in focus after reporting wider fourth quarter and full year 2025 losses, followed by a US$400 million at the market follow on equity offering in its common shares. See our latest analysis for Xenon Pharmaceuticals. The US$43.23 share price has seen a mixed stretch, with a 5.41% 1 month share price return and a 2.37% 7 day gain, but a modest year to date decline and recent pressure following the wider losses and US$400 million at the market offering. However, the 1 year total shareholder return of 16.77% and 5 year total shareholder return of 117.02% point to stronger longer term momentum. If this update on Xenon has you thinking about where the next potential mover might come from, take a look at our screener of 27 healthcare AI stocks as a starting shortlist. With wider losses, a US$400 million at the market offering, and the share price trading below some analyst targets, should you see Xenon as undervalued today or assume the market is already pricing in future growth? AdvertisementMost Popular Narrative: 22% Undervalued The most followed narrative pegs Xenon Pharmaceuticals' fair value at about $55.40 per share versus the recent $43.23 close. It frames the stock as materially discounted while hinging that gap on ambitious long term assumptions.  Expanding azetukalner into major depressive disorder and bipolar depression aligns with rising diagnosis and treatment rates for mood disorders and a strong appetite for novel mechanisms with rapid onset and better tolerability. This creates a pipeline in a product dynamic that can diversify and extend the company’s top line growth beyond epilepsy.  Read the complete narrative. Want to see what kind of revenue curve would need to sit behind that growth story? The narrative leans on aggressive top line expansion and a future earnings profile that implies a rich multiple on projected profitability. If you are curious how those moving pieces fit together, the full narrative breaks down the numbers behind that $55 plus fair value mark. Result: Fair Value of $55.40 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this hinges on clean late stage data for azetukalner and on payers not tightening reimbursement; either of these factors could quickly puncture that 22% undervaluation story. Find out about the key risks to this Xenon Pharmaceuticals narrative. Another View: Rich On Traditional Metrics While the popular narrative leans on future growth to call Xenon about 22% undervalued, the current P/B of 5.9x tells a tighter story. It sits higher than the US Biotechs average of 2.7x, yet below a 10.3x peer average, which leaves less obvious room for error if the growth narrative slips. Put simply, the market is already assigning a premium to Xenon, just not as steep as some peers. If growth or profitability timing shifts, how comfortable are you holding a stock that is not clearly cheap on balance sheet metrics alone? See what the numbers say about this price — find out in our valuation breakdown. NasdaqGM:XENE P/B Ratio as at Mar 2026Next Steps Torn between the bullish fair value story and that richer P/B multiple? Take a moment to look through the numbers yourself, weigh both the concerns and the upside, then check out 3 key rewards and 1 important warning sign to round out your view. Looking for more investment ideas? If Xenon is on your radar, do not stop there. Casting a wider net with targeted screeners can reveal opportunities you will not want to miss.  Target dependable cash generators by scanning our list of 15 dividend fortresses, especially if you want income to play a bigger role in your portfolio. Hunt for mispriced quality with our curated set of 46 high quality undervalued stocks, a quick way to spot companies where fundamentals and price look out of sync. Focus on financial strength first by reviewing the solid balance sheet and fundamentals stocks screener (39 results), so you are not caught holding businesses with fragile foundations when conditions change.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2616366821","isCrawlerRequest":true}